Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 3/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286100 | 1.00 | CA1 (0.61) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL11440044 | 0.92 | CA1 (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL10766580 | 0.91 | CA1 (0.52) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL28479851 | 0.88 | CA1 (0.53) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL5544560 | 0.88 | CA1 (0.53) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL6065014 | 0.88 | CA1 (0.53) | CA1CA2CA9F2PRSS1 | |
| Silver SCHEMBL29776718 | 0.86 | CA1 (0.55) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL598024 | 0.85 | CA1 (0.50) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL724542 | 0.85 | CA1 (0.59) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL25255094 | 0.85 | HTR6 (0.46) | CA1CA2CA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309012-A1 | ISOQUINOLINE COMPOUND, MANUFACTURING METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-09-19 | — | — | US | disclosed |
| CN-117177979-A | Cyclic dibenzyl tetrahydroisoquinoline compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-12-05 | — | — | CN | disclosed |
| US-11731965-B2 | Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-08-22 | — | — | US | disclosed |
| WO-2023104213-A1 | CYCLIC BISBENZYL TETRAHYDROISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-15 | — | — | WO | disclosed |
| CN-116253740-A | Cyclic dibenzyl isoquinoline compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-13 | — | — | CN | disclosed |
| CN-114375293-A | Isoquinoline compounds and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-04-19 | — | — | CN | disclosed |
| CN-109384780-B | Tetrahydro-protoberberine compounds, preparation method, application and pharmaceutical composition thereof | 中国科学院上海药物研究所 | 2022-04-08 | — | — | CN | disclosed |
| CN-113337602-A | Methods of treatment and biomarkers for MDM2 inhibitors | 苏州亚盛药业有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20200255421-A1 | TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| EP-3670511-A1 | TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-06-24 | — | — | EP | disclosed |
| EP-2463281-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130089-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-1274681-B1 | PROCESS FOR PRODUCING AMIDE COMPOUND | MITSUBISHI CHEM CORP (JP) | 2011-08-17 | — | — | EP | disclosed |
| CN-101272993-A | Siloxane polymerization in wallboard | UNITED STATES GYPSUM CO (US) | 2008-09-24 | — | — | CN | disclosed |
| EP-1274681-A1 | PROCESS FOR PRODUCING AMIDE COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6489474-B1 | A PROCESS FOR PRODUCING AN AMIDE COMPOUND BY SUBJECTING AN OXIME COMPOUND TO BECKMANN REARRANGEMENT IN A LIQUID PHASE, WHEREIN THE REACTION IS CARRIED OUT IN THE PRESENCE OF A NON-FLUORINE-CONTAINING SULFONIC ANHYDRIDE AND AN | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-12-03 | — | — | US | disclosed |
| WO-2001081302-A1 | PROCESS FOR PRODUCING AMIDE COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-11-01 | — | — | WO | disclosed |
| WO-1998020904-A2 | MICROPARTICLES FILLED WITH LIQUID ACTING ACCORDING TO A NEW PRINCIPLE AND THEIR USE AS DIAGNOSTIC AND THERAPEUTIC AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-05-22 | — | — | WO | disclosed |
| US-4689412-A | ANHYDRIDES OF SULFONIC ACIDS OR SULFURIC ACID HALF ESTERS, CATALYSTS | HULS AKTIENGESELLSCHAFT (DE) | 1987-08-25 | — | — | US | disclosed |
| US-4600542-A | Sulphonation products of naphthalene, processes for their preparation, and their use | KRAMER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309012-A1 | ISOQUINOLINE COMPOUND, MANUFACTURING METHOD THEREFOR, AND APPLICATION THEREOF | FURIN, REN, AQP1 | CA1 2973/4885CA2 3311/4885CA9 3838/4885 |
| US-20200255421-A1 | TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION | NOTUM, BHMT, CYP4F11 | CA1 2093/4885CA2 4460/4885CA9 4067/4885 |
| US-11731965-B2 | Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition | NOTUM, BHMT, CYP4F11 | CA1 2093/4885CA2 4460/4885CA9 4067/4885 |
| US-20120130089-A1 | METHOD FOR PRODUCING CYCLIC SULFONIC ACID ESTER AND INTERMEDIATE THEREOF | STS, TST, SULT1A1 | CA1 178/4885CA2 747/4885CA9 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.